
The Haemophilia Society of Singapore (HSS) recently hosted an educational webinar exploring gene therapy and its potential role in the future of haemophilia care.
Around 40 members of our community joined the session, including participants from Singapore and friends from the Haemophilia Society of Malaysia.
The webinar was presented by Professor Cihan Ay from the Medical University of Vienna, Austria, who shared an overview of the technology behind gene therapy, results from global clinical trials, and Austria’s experience with gene therapy as a clinical treatment option.
Prof Cihan began by explaining the principles behind gene therapy and how the approach differs from conventional haemophilia treatments.
He then shared findings from global, multi-year clinical trials, giving participants an opportunity to better understand the evidence behind gene therapy, as well as some of the considerations involved in its use as a treatment option.
An important part of the session was hearing about Austria’s experience with gene therapy in clinical practice. This provided a useful perspective on how the treatment is being introduced and accessed in a healthcare system where it is already available as a clinical option.
The presentation was followed by an extended Q&A, with participants asking a wide range of thoughtful questions about gene therapy and what it could mean for people living with haemophilia.
For HSS, these opportunities to hear directly from international experts are an important part of our efforts to provide members with access to current information about developments in haemophilia care.
We would like to thank Professor Cihan Ay for sharing his expertise and experience with our community, and everyone who joined the session and contributed to the discussion.
Professor Ay’s presentation slides are available below for anyone who would like to refer back to the material or learn more about the topics discussed during the webinar.